Abbott Labs (ABT)

Spun off their branded pharmaceutical business last year so now they have 40% in emerging markets and aiming to take closer to 50% over the next couple of years. Have some nutritional products along with their stents. Likes the product pipeline. Playing the increased demand for healthcare products in emerging markets through their branded generics. Continuing to see improved margins. Very attractive entry point. Yield of 1.6%.

One of the better ways to play pharmaceuticals. Amongst the big Pharmas it is one of the few that actually held up through the big selloff of the patent expiries in the mid-2000. Has a yield of about 2%.

(Top Pick May 17/12, Up 24.24%) He stayed with this and not the spin-out. This is about the best performing part of the market this year. Good dividend growth and very strong balance sheets.

(A Top Pick March 15/12. Up 33.59%.) Excellent stock that has done really well. Dividend yield.

Split off into 2 companies. This one and Abbvie (ABBV-N). Sold her holdings just before the split and wanted to get back in to this one, which was their pharmaceutical side. The other was too reliant on one drug. This is in nutrition, medical devices and branded generics. Have very big emerging-market exposure. Thinks there is big growth in branded generics. Dividend of just under 2%. Her target is high $30’s-$40 in one year.

Just initiated 3.6% dividend. Does like it. They may put growth back into business model or you have an activist shareholder that puts them up for sale. If stock stays flat you will collect the divided.

Split into 2 companies, this one and Abbvie (ABBV-N).He is not sold entirely on the split although he continues to hold both. On this one you get the nutritionals, some pharmaceuticals and medical devices. Valuation is not as attractive as it was before the split.

She sold ABv. But ABT-N has a very good basic business. Doesn’t understand why they don’t pay more dividend (1.6%) and thinks they may increase it soon.

Diversified. Have nutritionals, diagnostics (nice solid business), branded generics and medical devices where they have the leading drug eluting stents. 40% of sales are coming from high-growth emerging markets. Room for margin expansion. 1.64% dividend.

(Market Call Minute.) There is a spinoff coming on a restructuring, so be careful about tax implications. When it spins off, buy the medical device manufacturer.

Had a spinoff of their pharmaceutical side and this company now just represents the diagnostic and nutritional business. If you own, wait and see how things settle out for them.

It already had a bump up in price, but he is planning on holding both parts. Buying for new clients.

Splitting as of Jan 2^nd. Trading ‘as is’ in December. ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks. Thinks there is more upside in the Drug exploration part. Humera is one of the 5 biggest drugs globally. 5 drugs in clinical trials. A really good pipeline.

You can buy at its model price and when the company splits up it would increase value. The balance sheet has high growth parts buried within it. These smaller parts create more value. The pieces are worth more than the whole. 40 increases in dividends and very shareholder friendly. He would stay with both after the split until you can review balance sheets.

(Market Call Minute) Would sell on the split. It is too complicated to be there with the split.